Product News

Share this article:
GlaxoSmithKline says the US launch of HPV vaccine Cervarix will feature a slightly lower price than that of Merck's vaccine Gardasil, the Financial Times reports. GSK's new entrant will carry a wholesale cost of $386 for a three-course dose, compared with $399 for rival Gardasil, making the GSK vaccine more attractive for payers. The price strategy already has helped GSK win a vaccine contract in the UK.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.